In Her2-negative BC patients treated with metronomic apecitabine, higher abundance of Slackia was associated with lower progression-free survival (PFS), while higher abundance of Blautia obeum was associated with higher PFS [21]. The gene discussed is ERBB2; the disease is breast cancer.